advertisement
Kiuchi Y 21
Showing records 1 to 21 | Display all abstracts from Kiuchi Y96144 The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
Onoe H
Journal of clinical medicine 2021; 10:
96132 Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Bell K
Ophthalmology 2022; 129: 406-413
96530 Corneal Higher-Order Aberrations after Microhook ab Interno Trabeculotomy and Goniotomy with the Kahook Dual Blade: Preliminary Early 3-Month Results
Onoe H
Journal of clinical medicine 2021; 10:
96144 The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
Hirooka K
Journal of clinical medicine 2021; 10:
96530 Corneal Higher-Order Aberrations after Microhook ab Interno Trabeculotomy and Goniotomy with the Kahook Dual Blade: Preliminary Early 3-Month Results
Hirooka K
Journal of clinical medicine 2021; 10:
96132 Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Ozaki M
Ophthalmology 2022; 129: 406-413
96530 Corneal Higher-Order Aberrations after Microhook ab Interno Trabeculotomy and Goniotomy with the Kahook Dual Blade: Preliminary Early 3-Month Results
Okumichi H
Journal of clinical medicine 2021; 10:
96132 Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Mori K
Ophthalmology 2022; 129: 406-413
96144 The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
Nagayama M; Hirota A
Journal of clinical medicine 2021; 10:
96132 Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Mizoguchi T
Ophthalmology 2022; 129: 406-413
96530 Corneal Higher-Order Aberrations after Microhook ab Interno Trabeculotomy and Goniotomy with the Kahook Dual Blade: Preliminary Early 3-Month Results
Murakami Y
Journal of clinical medicine 2021; 10:
96132 Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Nakano S
Ophthalmology 2022; 129: 406-413
96530 Corneal Higher-Order Aberrations after Microhook ab Interno Trabeculotomy and Goniotomy with the Kahook Dual Blade: Preliminary Early 3-Month Results
Kiuchi Y
Journal of clinical medicine 2021; 10:
96144 The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
Mochizuki H
Journal of clinical medicine 2021; 10:
96132 Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Porporato N
Ophthalmology 2022; 129: 406-413
96144 The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
Sagara T
Journal of clinical medicine 2021; 10:
96132 Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Ikeda Y
Ophthalmology 2022; 129: 406-413
96144 The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
Suzuki K; Okumichi H
Journal of clinical medicine 2021; 10:
96132 Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Chihara E
Ophthalmology 2022; 129: 406-413
96144 The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients
Kiuchi Y
Journal of clinical medicine 2021; 10:
96132 Association of the CYP39A1 G204E Genetic Variant with Increased Risk of Glaucoma and Blindness in Patients with Exfoliation Syndrome
Inoue K; Manabe S; Hayashi K; Higashide T; Ideta R; Tokumo K; Kiuchi Y; Nakano M; Ueno M; Kinoshita S; Tashiro K; Sotozono C; Inatani M; Sugiyama K; Kubota T; Li Z; Wang Z; Khor CC; Aung T
Ophthalmology 2022; 129: 406-413